Show simple item record

dc.contributor.authorDawson, M
dc.contributor.authorJohnston, D
dc.contributor.authorTaylor, G
dc.contributor.authorMoore, Michael
dc.date.accessioned2010-11-30T17:52:54Z
dc.date.available2010-11-30T17:52:54Z
dc.date.issued1986
dc.identifier.citationLymphokine activated killing of fresh human leukaemias. 1986, 10 (6):683-8 Leuk Resen
dc.identifier.issn0145-2126
dc.identifier.pmid3487007
dc.identifier.doi10.1016/0145-2126(86)90273-0
dc.identifier.urihttp://hdl.handle.net/10541/116742
dc.description.abstractThe relative susceptibility of 10 human leukaemias comprising acute phase leucocytes from 5 acute myeloid and 5 lymphoid neoplasms, and 2 immunoblastic lymphomas to killing by peripheral blood mononuclear cells (PBMC), before and after target cell treatment with phytohaemagglutinin (PHA), and by interleukin-2 (IL-2) activated peripheral blood lymphocytes (PBL) was investigated in short term 51Cr release assays using effector cells from 10 allogeneic donors. Optimal lectin-dependent cellular cytotoxicity (LDCC) was verified against K562 and L1210 cells and lymphokine-activated killing (LAK) against K562 and Daudi cells. Under these conditions, the majority of the leukaemias tested revealed only a finite sensitivity to any of the cytotoxic mechanisms, which was dependent on the donor origin of the effectors. The leukaemias were more consistently susceptible to LDCC than LAK and removal of adherent cells to enrich for the latter activity in effector populations, was ineffective. Lymphocytes from a patient in long term (greater than 5 yr) remission exhibited LAK against the autologous target E84, a natural killer (NK)-sensitive acute myelomonocytic leukaemia. These cells failed to cross-compete for lysis of K562 by LAK cells, suggesting the existence of different recognition structure(s) on the two targets.
dc.language.isoenen
dc.subjectLeukaemiaen
dc.subject.meshCell Line
dc.subject.meshCells, Cultured
dc.subject.meshCytotoxicity, Immunologic
dc.subject.meshHumans
dc.subject.meshImmunity, Cellular
dc.subject.meshImmunologic Surveillance
dc.subject.meshInterleukin-2
dc.subject.meshKiller Cells, Natural
dc.subject.meshLectins
dc.subject.meshLeukemia
dc.titleLymphokine activated killing of fresh human leukaemias.en
dc.typeArticleen
dc.contributor.departmentDepartment of Immunology, Paterson Laboratories, Christie Hospital and Holt Radium Institute, Manchester M20 9BX.en
dc.identifier.journalLeukemia Researchen
html.description.abstractThe relative susceptibility of 10 human leukaemias comprising acute phase leucocytes from 5 acute myeloid and 5 lymphoid neoplasms, and 2 immunoblastic lymphomas to killing by peripheral blood mononuclear cells (PBMC), before and after target cell treatment with phytohaemagglutinin (PHA), and by interleukin-2 (IL-2) activated peripheral blood lymphocytes (PBL) was investigated in short term 51Cr release assays using effector cells from 10 allogeneic donors. Optimal lectin-dependent cellular cytotoxicity (LDCC) was verified against K562 and L1210 cells and lymphokine-activated killing (LAK) against K562 and Daudi cells. Under these conditions, the majority of the leukaemias tested revealed only a finite sensitivity to any of the cytotoxic mechanisms, which was dependent on the donor origin of the effectors. The leukaemias were more consistently susceptible to LDCC than LAK and removal of adherent cells to enrich for the latter activity in effector populations, was ineffective. Lymphocytes from a patient in long term (greater than 5 yr) remission exhibited LAK against the autologous target E84, a natural killer (NK)-sensitive acute myelomonocytic leukaemia. These cells failed to cross-compete for lysis of K562 by LAK cells, suggesting the existence of different recognition structure(s) on the two targets.


Files in this item

This item appears in the following Collection(s)

Show simple item record